{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:54:17Z","timestamp":1791482057002,"version":"4.3.4"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008021","name":"Bristol-Myers Squibb Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgery"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.surg.2020.04.057","type":"journal-article","created":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T20:51:17Z","timestamp":1593809477000},"page":"610-616","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["A phase 1b trial of concurrent immunotherapy and irreversible electroporation in the treatment of locally advanced pancreatic adenocarcinoma"],"prefix":"10.1016","volume":"168","author":[{"given":"Conor","family":"O\u2019Neill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Traci","family":"Hayat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Healey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"Robert C.G.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.surg.2020.04.057_bib1","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/SLA.0b013e318263da2f","article-title":"Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a \u201ctrue\u201d R0 resection?","volume":"257","author":"Konstantinidis","year":"2013","journal-title":"Ann Surg"},{"key":"10.1016\/j.surg.2020.04.057_bib2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jso.24642","article-title":"Overcoming the resistance of pancreatic cancer to immune checkpoint inhibitors","volume":"116","author":"Skelton","year":"2017","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.surg.2020.04.057_bib3","first-page":"925s","article-title":"Systemic and local immunosuppression in pancreatic cancer patients","volume":"7","author":"von Bernstorff","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.surg.2020.04.057_bib4","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.surg.2020.04.057_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000267","article-title":"Preoperative\/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages","volume":"7","author":"Gillen","year":"2010","journal-title":"PLoS Med"},{"key":"10.1016\/j.surg.2020.04.057_bib6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/hpb.12078","article-title":"2564 resected periampullary adenocarcinomas at a single institution: trends over three decades","volume":"16","author":"He","year":"2014","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.surg.2020.04.057_bib7","doi-asserted-by":"crossref","first-page":"819","DOI":"10.18632\/oncoscience.198","article-title":"Revisiting stroma in pancreatic cancer","volume":"2","author":"Khan","year":"2015","journal-title":"Oncoscience"},{"key":"10.1016\/j.surg.2020.04.057_bib8","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1158\/0008-5472.CAN-14-2397","article-title":"Ormeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancer","volume":"75","author":"Khan","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.surg.2020.04.057_bib9","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/SLA.0000000000001441","article-title":"Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy","volume":"262","author":"Martin","year":"2015","journal-title":"Ann Surg"},{"key":"10.1016\/j.surg.2020.04.057_bib10","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.hpb.2016.07.007","article-title":"An update on the role of irreversible electroporation in locally advanced pancreatic adenocarcinoma","volume":"18","author":"Martin","year":"2016","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.surg.2020.04.057_bib11","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.suc.2016.07.010","article-title":"Management of locally advanced pancreatic cancer","volume":"96","author":"Martin","year":"2016","journal-title":"Surg Clin North Am"},{"key":"10.1016\/j.surg.2020.04.057_bib12","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.hpb.2018.12.004","article-title":"A\u00a0prospective, multi-institution assessment of irreversible electroporation for treatment of locally advanced pancreatic adenocarcinoma: initial outcomes from the AHPBA pancreatic registry","volume":"21","author":"Holland","year":"2019","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.surg.2020.04.057_bib13","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/jso.24404","article-title":"Irreversible electroporation in locally advanced pancreatic cancer: a call for standardization of energy delivery","volume":"114","author":"Martin","year":"2016","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.surg.2020.04.057_bib14","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1245\/s10434-018-07144-3","article-title":"Evaluating the regulatory immunomodulation effect of irreversible electroporation (IRE) in pancreatic adenocarcinoma","volume":"26","author":"Pandit","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2020.04.057_bib15","article-title":"Immunologic response to tumor ablation with irreversible electroporation","volume":"7","author":"Li","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.surg.2020.04.057_bib16","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.pan.2017.11.011","article-title":"International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017","volume":"18","author":"Isaji","year":"2018","journal-title":"Pancreatology"},{"key":"10.1016\/j.surg.2020.04.057_bib17","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1200\/EDBK_200861","article-title":"What makes a pancreatic cancer resectable?","volume":"38","author":"Evans","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.surg.2020.04.057_bib18","first-page":"4","article-title":"Irreversible electroporation of stage 3 locally advanced pancreatic cancer: optimal technique and outcomes","volume":"1","author":"Martin","year":"2015","journal-title":"J\u00a0Vis Surg"},{"key":"10.1016\/j.surg.2020.04.057_bib19","first-page":"329","article-title":"Irreversible electroporation of locally advanced pancreatic neck\/body adenocarcinoma","volume":"6","author":"Martin","year":"2015","journal-title":"J\u00a0Gastrointest Oncol"},{"key":"10.1016\/j.surg.2020.04.057_bib20","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/978-3-540-71279-4_10","article-title":"Primary advanced unresectable pancreatic cancer","volume":"177","author":"Wilkowski","year":"2008","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.surg.2020.04.057_bib21","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/13651820510028936","article-title":"Complications of pancreatic surgery","volume":"7","author":"Ho","year":"2005","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.surg.2020.04.057_bib22","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2019.37.4_suppl.298","article-title":"Phase I study of nivolumab (Nivo)\u00a0+ nab-paclitaxel (nab-P)\u00a0+ gemcitabine (Gem) in advanced pancreatic cancer (APC)","volume":"37","author":"Wainberg","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.surg.2020.04.057_bib23","doi-asserted-by":"crossref","first-page":"275","DOI":"10.21037\/jgo.2018.01.14","article-title":"Percutaneous irreversible electroporation with systemic treatment for locally advanced pancreatic adenocarcinoma","volume":"9","author":"Leen","year":"2018","journal-title":"J\u00a0Gastrointest Oncol"},{"key":"10.1016\/j.surg.2020.04.057_bib24","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.surg.2020.04.057_bib25","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/nyas.13625","article-title":"Regulatory T cells: a potential target in cancer immunotherapy","volume":"1417","author":"Shitara","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.surg.2020.04.057_bib26","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1146\/annurev.immunol.22.012703.104702","article-title":"Central memory and effector memory T cell subsets: function, generation, and maintenance","volume":"22","author":"Sallusto","year":"2004","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.surg.2020.04.057_bib27","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1111\/cas.13758","article-title":"Activation of central\/effector memory T cells and T-helper 1 polarization in malignant melanoma patients treated with anti-programmed death-1 antibody","volume":"109","author":"Yamaguchi","year":"2018","journal-title":"Cancer Sci"},{"key":"10.1016\/j.surg.2020.04.057_bib28","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.3389\/fimmu.2018.01613","article-title":"Circulating T cell subpopulations correlate with immune responses at the tumor site and clinical response to PD1 inhibition in non-small cell lung cancer","volume":"9","author":"Manjarrez-Orduno","year":"2018","journal-title":"Front Immunol"}],"container-title":["Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039606020302713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039606020302713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T10:54:02Z","timestamp":1758538442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039606020302713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0039606020302713"],"URL":"https:\/\/doi.org\/10.1016\/j.surg.2020.04.057","relation":{},"ISSN":["0039-6060"],"issn-type":[{"value":"0039-6060","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 1b trial of concurrent immunotherapy and irreversible electroporation in the treatment of locally advanced pancreatic adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.surg.2020.04.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}